Autoimmune liver disease

Annals of Gastroenterology

Volumn 17, Issue 1, 2004, Pages 51-58

  Petrogiannopoulos, C ^a,b   Papamichael, K ^a   Goumas, K ^a   Soutos, D ^a  

^a RED CROSS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Autoimmune hepatitis; Overlap syndromes; Primary biliary cirrhosis; Primary sclerosing cirrhosis

Indexed keywords

EID: 49749105265     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Meyer zum Bushenfelde KH, Lohse AW, Manns M, Poralla T. Autoimmunity and liver disease. Hepatology 1990;1:354-363
2. Liu CC, Young L, Young D. Lymphocyte-mediated cytolisis and disease. N Eng J Med 1996; 335:1651-1659
3. Gish R G, Mason A. Autoimmune liver disease. Current standards, future directions. Clin Liver Dis 2001; 5:287-314
4. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28:360-365
5. Czaja AJ. Diagnosis and therapy of autoimmune liver disease. Med Clin N Am 1996; 80: 973-994
6. Michail A, Papatheodoridis GB. Autoimmune hepatitis. Modern views. Archives of Hellinic Medicine 2001; 18:485-495
7. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000; 32 (suppl 1):181-197
8. Prandota J. Possible pathomechanism of autoimmune hepatitis. Am J Ther 2003 Jan-Feb;10: 51-57
9. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002 Aug;6: 397-417
10. Koskinas J, McFarlane BM, McFarlane IG, Williams R. Cellular and humoral immunity to the asialoglycoprotein receptor in autoimmune hepatitis during treatment, correlation with disease activity. Hepatology 1993; 18:173-179
11. Manns M, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 dp1. J Clin Invest 1989; 83:1066-1072
12. Stasney P, Ball EJ, Dry PJ, Nunez J. Thehuman immune response region (HLA-D) and disease susceptibility. Immunol Rev 1983; 70:113-153
13. Johnson PJ, McFarlane IG. Meeting report,International autoimmune hepatitis group. Hepatology 1993; 18:998-1005
14. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clinic Proceedings 1990; 65:23-30
15. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002 Nov;22: 365-378
16. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2003 Sep; 2:241-247
17. Sanchez-Urdazpal L, Czaja AJ, Rakela J, Ludwig J. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic hepatitis. Hepatology 1992; 15:215-229
18. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-963
19. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1:735-737
20. Pratt DS, Flavin DP, Karlan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996; 110: 271-274
21. Prince HE, Ettenger RB, Dorey FJ, Fine RN, Fahey JC. Azathioprine suppression of natural killer activity and antibody-depended cellular cytotoxicity in renal transplant recipients. J Clin Immunol 1984; 4:312-318
22. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrwal. Hepatology 1988; 8:781-784
23. Manns MP. Antibodies to soluble liver antigen,specific marker of autoimmune hepatitis. J Hepatol 2000; 33:326-328
24. Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000 Apr 29; 355:1510-1515
25. Watanabe A, Wakabayashi H, Yasumura S, Shimizu Y, Higuchi K, Nishioka M. Autoinumme hepatitis types Iia and IV in young men. J Med 1997; 28:347-362
26. Wanless IR. Use of corticosteroid therapy in autoimmune hepatitis resulting in the resolution of cirrhosis. J Clin Gastroenterol 2001 May-Jun; 32:371-372
27. Krawitt E. Autoimmune hepatitis. N Engl J Med 1996; 334:897-903
28. Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis, an overview. Eur J Intern Med 2002 Aug; 13(5): 293-303
29. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003 Jul 5; 362:53-61
30. Neuberger J 'Primary biliary cirrhosis' Lancet 1997; 350:875-879
31. Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003; 1:89-95
32. Lee SM, Ko SH, Park JE, Cha SH. Expression of a recombinant branched chain alpha-oxo acid dehydrogenase complex E2 (BCOADC-E2) in insect cells and its immunoreactivity to autoinumme sera. Exp Mol Med 1998; 30:65-71
33. Invernizzi P, Battezzati PM, Crosignani A, Zermiani P, Bignotto M, Del Papa N et al. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol 1998; 114:448-454
34. Nickowitz RE, Wozniak RW, Schaffner F, Worman HJ. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. Gastroenterology 1994; 106:193-199
35. Levy C, Lindor KD. Current managment of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2003; 38:24-37
36. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gstroenterology 1992; 102:2077-2080
37. Beukers R, Schalm SW. Immunosuppressive therapy for primary biliary cirrhosis. J Hepatol 1992; 14:1-6
38. Bodenheimer HJ, Schaffner F, Pezzulo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 1988; 95: 124-129
39. Cook CG, Multigan S, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40:159-185
40. Degott C, Zafrani ES, Gallard P, Baalkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxexolic acid treatment on histology progression. Hepatology 1999; 29:1007-1012
41. Guanabens N, Parees A, Del Rio L, Roca M, Gomez R, Munoz J et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992; 15:345-349
42. Jones DEJ, James OFW, Bassentine MF. Ursodeoxyholic: acid therapy in primarycirrhosis. Hepatology 1995; 21:1469-1472
43. Mitchison HC, Palmer JM, Bassentine MF, Waston AJ, Record CO, James OFW. A controlled trial of prednisolone treatment in primary biliary cirrhosis.Three year results. J Hepatol 1992; 15:336-344
44. Poupon RE, Bonnand AM, Chtetien Y, Poupon R, UDCA-PBC STUDY GROUP. Ten-year survival in ursodeoxyholic acid-treatment patients with primary biliary cirrhosis. 1999; 29:1668-1671
45. Van Leeuwen DJ, Sood G, Ferrante D, Lazenby AJ, Sellers MJ. A 38-year-old African-American woman with an unussually rapid progression of primary biliary cirrhosis, a missed opportunity. Semin Liver Dis 2002 Nov; 22:395-406
46. Southern PB, Davies MH, Indication and assessment for liver transplantation. Clin Med 2002 Jul-Aug; 2:313-316
47. Bachrich T, Thalhammer T, lager W, Hastmayer P, Alihodzic B, Bakos S, et al. Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver disease. Hepatology 2001 May; 35(5):1053-1059
48. Boberg KM, Lundin KEA, Schrumpf E. Etiology and pathogenesis in primary sclerosing cholangitis. Scand J Gastroenterol 1994; suppl 204:47-58
49. Cecere A, Tancredi L, Gattoni A. Primary sclerosing cholangitis. Panminerva Med 2002 Dec; 44:313-323
50. Ponsioen CIJ, Tytgad GNJ. Primary sclerosing cholangitis,a clinical review. Am J Gastroenterol 1998; 93:515-523
51. Porayko MK, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis, a progressive disease? Semin Liver Dis 1991; 11:18-25
52. Luketic VAC, Gomez DA, Sanyal AJ, Shiffman ML. An atypical presentation for primary sclerosing cholangitis. Dig Dis Sci 1997; 42 (10):2009-2016
53. Lee YH, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924-931
54. Rodes J, Pares A. Treatment of pruritus of chronic cholestasis. Cholestasis 1994: 267-281
55. Wiesner RH. La Russo NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79:200-206
56. Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994; 69:969-976
57. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991; 11:11-17
58. Rosen CB, Nagomey DM. Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 1991; 11:26-30
59. Roozendaal C, De Jong MA, Van Den Berg AP, Van Wijk RT, Limburg PC, Kallenberg CG. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000 May; 32:734-741
60. Ohana SI, Okasaki & Harijo Y, Uchida K Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol. 1998; 93:1334-1339
61. Vogel A, Wedemeyer H, P Manns M, Strassburg CP. Autoimmune hepatitis and overlap syndromes. J Gastroenterol Hepatol 2002 Dec; 17suppl 3:389-398
62. Lohr HE Autoimmune hepatitis and overlap syndrome, therapy. Schweiz Rundsch Med Prax 2002 Aug 21; 91:1347-1351
63. Dienes HP, Erberich H, Dries V, Schirmacher P, Lohse A. Autoimmune hepatitis and overlap syndromes. Clin Liver Dis 2002 May; 6:349-362
64. Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis,an evaluation of a modified scoring system. Am J Gastroenterol 2002 May; 97:1191-1197
65. Kanzler S, Bozkurt S, Herkel J, Galle PR, Dienes HP, Lohse AW. Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome). Dtsch Med Wochenschr 2001 Apr 20; 126:450-456
66. Gunsar F, Akarea US, Ersoz G, Karasu Z, Yuse G, Batur Y. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis -autoimmune hepatitis overlap syndrome. Hepatogastroenterology 2002 Sep-Oct; 49:1195-2000
67. Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K et al. Primary Biliary cirrhosis with additional features of autoimmune hepatits,response to therapy with ursodeoxycholic acid. Hepatology 2002 Feb; 35:409-413
68. Chazouilleres O, Wendum. D, Serfaty L, Montembault S, Rosmorduc O, Poupon R et al. Primary biliary cirrhosis-autoimmune hepatits overlap syndrome, clinical features and response to therapy. Hepatology 1998 Aug; 28:296-301
69. Podymova SD. Syndrome of cross-over between primary biliary cirrhosis and autoirmnune hepatitis. Ter Arkh 2002; 74:41-44
70. Criga T, Tromm A, Muller KM, May B. Overlap syndrome between autoimmune hepatitis and primary sclerosing cholangitis in two cases. Eur J Gastroenterol Hepatol 2000 May; 12: 559-564
71. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis, an evaluation of a modified scoring system. J Hepatol 2000 Oct; 33: 537-542
72. Hatzis GS, Vassiliou VA, Delladetsima. Overlap syndrome of primary sclerosing cholangitis and autoimmune hepatitis. Eur J Gastroenterol Hepatol 2001 Feb; 13:203-206
73. McNair ANB, Moloney M, Portman BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998; 93:777-784
74. Heathcote J. Autoimmune cholangitis. Gut 1997; 40:440-442
75. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF et al. Antimitochondrial antibody negative primary biliary cirrhosis, a distinct syndrome of autoimmune cholangitis. Gut 1994; 35:260-265
76. Sherlock DM. Autoimmune cholangitis,a unique entity? Mayo Clin Proc 1998; 73:184-190
77. Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Ain J Surg Pathol 1994; 18:91-99
78. Yoossef WI, Tavill AS. Connective tissue diseases and the liver. J Clin Gastroenterol 2002 Oct; 35:345-349